Connect Biopharma (CNTB) Expected to Post Earnings on Wednesday

Connect Biopharma (NASDAQ:CNTB) is anticipated to issue its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.32) per share and revenue of $0.1090 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Connect Biopharma (NASDAQ:CNTB) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.05). The business had revenue of $0.02 million during the quarter. On average, analysts expect Connect Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Connect Biopharma Price Performance

Shares of CNTB opened at $2.07 on Wednesday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.01. Connect Biopharma has a twelve month low of $1.23 and a twelve month high of $3.82. The stock has a market capitalization of $130.33 million, a P/E ratio of -1.80 and a beta of -0.23. The company has a 50 day moving average of $2.22 and a 200-day moving average of $2.48.

Insider Buying and Selling at Connect Biopharma

In related news, Director James Huang purchased 150,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was acquired at an average cost of $2.48 per share, for a total transaction of $372,000.00. Following the completion of the purchase, the director owned 13,310,000 shares in the company, valued at approximately $33,008,800. This represents a 1.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 22.60% of the company’s stock.

Hedge Funds Weigh In On Connect Biopharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC bought a new stake in shares of Connect Biopharma during the 4th quarter valued at $2,235,000. Millennium Management LLC acquired a new stake in shares of Connect Biopharma during the 4th quarter worth $133,000. Royal Bank of Canada bought a new position in shares of Connect Biopharma in the fourth quarter worth $114,000. Persistent Asset Partners Ltd bought a new position in shares of Connect Biopharma in the fourth quarter worth $76,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Connect Biopharma in the fourth quarter valued at about $228,000. Institutional investors own 58.72% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of Connect Biopharma in a report on Tuesday, May 26th. They set a “buy” rating and a $6.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Connect Biopharma in a research note on Thursday, June 25th. Wall Street Zen cut shares of Connect Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, June 28th. Weiss Ratings downgraded Connect Biopharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 30th. Finally, Oppenheimer began coverage on shares of Connect Biopharma in a research report on Thursday, July 9th. They set an “outperform” rating and a $8.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.29.

Connect Biopharma Company Profile

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.